|
Imatinib |
|
Home > Database
> Treatment
> Imatinib
(Gleevec, STI571)
|
|
|
Contents
|
|
|
|
Medulloblastoma
|
|
|
|
R. Morosetti, D. Meco, C. Dominici,
T. Servidei, A. Riccardi, A. M. Di Francesco, G. Cusano, R. Riccardi
Antitumor activity of imatinib mesylate in
medulloblastoma cell lines and xenografts
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8554
|
|
|
Meningioma
|
|
|
|
|
Reardon DA, Norden AD,
Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan
S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY,
Friedman HS.
Phase II study of Gleevec(®) plus hydroxyurea
(HU)
in adults with progressive or recurrent meningioma.
J Neurooncol. 2011
Sep 22. [Epub ahead of
print]
.JPG) Abstract | .gif)
Related articles
|
|
|
Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy
TF, Abrey LE, Fine HA, Chang
SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J,
Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD
Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas
(North American Brain Tumor Consortium Study 01-08)
Neuro Oncol. 2009 Mar 17; [Epub ahead of print]
Abstract
|
|
|
|
